Ablation Treatment

COMBINATION_PRODUCT3 trials

Sponsors

University of Chicago, Neurotronic, Inc., Boston Scientific Corporation

Conditions

Atrial FibrillationDiabetes Mellitus, Type 2Foregut Carcinoid TumorGI CancerGI CarcinomaGallbladder AdenocarcinomaGastric AdenocarcinomaHypertension

Phase 1

Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

RecruitingNCT05369065

Neurotronic, Inc.Diabetes Mellitus, Type 2, Hypertension

Start: 2022-01-27End: 2029-01-31Target: 60Updated: 2023-03-22

Phase 2

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

WithdrawnNCT04931420

University of ChicagoForegut Carcinoid Tumor, Gallbladder Adenocarcinoma, Gastric Adenocarcinoma +5

Start: 2022-05-19End: 2027-11-01Updated: 2024-07-31

Unknown Phase

Feasibility Study on the FARAVIEW Technology

CompletedNCT06175234

Boston Scientific CorporationAtrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation

Start: 2024-04-03End: 2025-06-06Updated: 2025-09-17

Related Papers

Lesion Durability of the Second Generation Pentaspline Pulsed Field Ablation Catheter <i>NAVIGATE-PF</i> Phase 2 Results.

2026-04-01

Visualization of PFA During PVI With the Second-Generation Pentaspline Catheter: NAVIGATE-PF Phase 1 Results.

2025-12-30